Published in Cancer Metastasis Rev on November 18, 2016
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Dendritic cells and the control of immunity. Nature (1998) 56.54
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Cancer-related inflammation. Nature (2008) 34.21
Immunity, inflammation, and cancer. Cell (2010) 28.27
Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 26.08
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Cancer genome landscapes. Science (2013) 25.33
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 24.36
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest (2007) 20.19
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 13.44
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature (2003) 13.00
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol (2006) 12.29
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Taking dendritic cells into medicine. Nature (2007) 11.82
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Clonal evolution in cancer. Nature (2012) 11.07
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 9.82
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol (2008) 9.25
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature (2011) 8.62
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med (1992) 8.46
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 8.00
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 7.90
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 7.65
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res (2004) 7.56
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
SHIP represses the generation of alternatively activated macrophages. Immunity (2005) 7.41
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol (2013) 7.10
Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell (2009) 7.09
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol (2011) 6.96
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res (2007) 6.60
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell (2010) 6.33
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci U S A (2004) 5.89
Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol (2006) 5.82
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol (2009) 5.37
Trophic macrophages in development and disease. Nat Rev Immunol (2009) 5.37
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell (2009) 5.22
Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol (2005) 5.20
CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04
A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
Tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 4.69
Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol (2007) 4.65